Rosuvastatin t-butylamine
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Category
- Pharmaceutical Intermediates
Inist ST
- Membership
- VIP
- Recent Visit
- Nov 21, 2024
- Country / Year Established
-
South Korea
/
2000
- Business type
- Manufacturer
- Verified Certificate
-
16
| Product name | Rosuvastatin t-butylamine | Certification | - |
|---|---|---|---|
| Category | Pharmaceutical Intermediates | Ingredients | - |
| Keyword | active pharmaceutical ingredient , api , rosuvastatin tba | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
| Category |
Hyperlipidemia treatment
| Spec |
JP / IHS
| Description |
Rosuvastatin t-butylamine is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken by mouth.
Rosuvastatin is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Kim Kuk-hyun
- Address
- Geumwang-Eup, 500 Shinaero , Eumseong-gun, Chungcheongbuk-do, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 2000
- Company introduction
-
Having persistent enthusiasm, INIST ST is trying to contribute to the society and community by delivering healthier life from age 0 to 110 years through research and innovation. Since its establishment in 2000, INIST ST has been accomplishing rapid growth with passion, confidence and trust between customers and the company. INIST ST has developed non-cytotoxic anti-cancer, high quality generic & value-added API and supplied to the domestic and overseas markets. INIST ST has intensive R&D function in exploration of drug candidate and process development of small molecules. As result of those efforts, INIST ST has achieved multiple crystal and process patents and become partner of several government sponsoring development projects.
- Main Markets
-
Japan
Taiwan
Turkey
U.S.A
- Main Product
Related Products
Limonin
3-amino-2-methylamino-5-(trifluoromethyl)pyridine
Cas 62595-74-8
beta-cyclodextrin
GBL Gamma-Butyrolactone USA Canada 99.9% Wheel Cleaner
